



Clinical Edit Criteria Proposal

Drug/Drug Class: Raptiva[®] Clinical Edit
 Implementation Date: December 22, 2004
 Prepared for: Missouri Medicaid
 Prepared by: Heritage Information Systems, Inc.

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: Ensure appropriate utilization of Raptiva[®] (efalizumab).

Why was this Issue Selected: This product is prescribed for adults with moderate to severe plaque psoriasis who are candidates for phototherapy or other systemic (oral or injected) treatments.

Program-specific information:	Drug	Dosage Form	Cost per Dosage Form
	<ul style="list-style-type: none"> • Raptiva[®] (efalizumab) 	125mg vial	<i>Approximately \$14,000 for one year of continuous treatment</i>

Setting & Population: Patients 18 years of age or older.

Type of Criteria:

<input type="checkbox"/> Increased risk of ADE	<input type="checkbox"/> Non-Preferred Agent
<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/>

Data Sources:

<input type="checkbox"/> Only administrative databases	<input checked="" type="checkbox"/> Databases + Prescriber-supplied
--	---

Setting & Population

- Drug for review: Raptiva[®] (efalizumab)
- Age range: 18 years of age and older
- Gender: Male and female

Approval Criteria

- 1) Patient is diagnosed with chronic moderate to severe plaque psoriasis (ICD-9=696).
- 2) The patient presents one, or more, of the following:
 - Psoriasis is affecting \geq 5-10% of the patient's body surface area.
 - Patient is disabled by the psoriasis.
 - The psoriasis has a significant impact on the patient's quality of life.
 - Patient has psoriatic arthritis
- 3) Phototherapy is contraindicated or unavailable, or the psoriasis is resistant to phototherapy.
- 4) The patient has received systemic treatment for psoriasis using one of the following agents:
 - Cyclosporine
 - Methotrexate
 - Soriatane (Acitretin[®])
 - Isotretinoin (Accutane[®])
 - Hydroxyurea (Hydrea[®], Droxia[®])
 - Sulfasalazine (Azulfadine[®])
 - 6-Thioguanine (Tabloid[®])

Denial Criteria

- Absence of approval criteria
- Age < 18 years

References

1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2004.
2. Facts and Comparisons, pg. 1548c; 2004.
3. Raptiva Package Insert; Genentech, Inc. South San Francisco, CA. October 2003.

